How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

711 results for

Hairy Cell Leukemia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hairy cell leukaemia

-stimulating factors may have a role in therapy for hairy cell leukaemia. Definition Hairy cell leukaemia (HCL) is an uncommon, indolent, mature B-cell neoplasm. It was described as a distinct clinical entity in 1958. Foucar K, Falini B, Catovsky D, et al. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2, 4th ed. Geneva, Switzerland: World Health Organization Press; 2008:188-90. Seen under the microscope, the cells have delicate cytoplasmic projections (...) Hairy cell leukaemia Hairy cell leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hairy cell leukaemia Last reviewed: February 2019 Last updated: November 2018 Summary A B-cell malignancy that is characterised commonly by symptoms of fatigue, a markedly enlarged spleen, and a distinctive histological appearance on peripheral blood smear and bone marrow biopsy. The disease is not curable. However, it is highly

2018 BMJ Best Practice

2. Moxetumomab pasudotox-tdfk (Lumoxiti) - To treat hairy cell leukemia

Moxetumomab pasudotox-tdfk (Lumoxiti) - To treat hairy cell leukemia Drug Approval Package: LUMOXITI U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LUMOXITI Company: AstraZeneca AB Application Number: 761104 Approval Date: 09/13/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF

2018 FDA - Drug Approval Package

4. Hairy cell leukaemia

-stimulating factors may have a role in therapy for hairy cell leukaemia. Definition Hairy cell leukaemia (HCL) is an uncommon, indolent, mature B-cell neoplasm. It was described as a distinct clinical entity in 1958. Foucar K, Falini B, Catovsky D, et al. Hairy cell leukemia. In: WHO classification of tumours of haematopoietic and lymphoid tissues, vol 2, 4th ed. Geneva, Switzerland: World Health Organization Press; 2008:188-90. Seen under the microscope, the cells have delicate cytoplasmic projections (...) Hairy cell leukaemia Hairy cell leukaemia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hairy cell leukaemia Last reviewed: February 2019 Last updated: November 2018 Summary A B-cell malignancy that is characterised commonly by symptoms of fatigue, a markedly enlarged spleen, and a distinctive histological appearance on peripheral blood smear and bone marrow biopsy. The disease is not curable. However, it is highly

2017 BMJ Best Practice

5. Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine Full Text available with Trip Pro

Multifocal brain involvement in a patient with hairy cell leukemia successfully treated with rituximab and cladribine Brain involvement, although rare, can occur in HCL.The combination of cladribine and rituximab is a highly effective treatment of HCL with brain involvement.

2017 Blood advances

6. Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature Full Text available with Trip Pro

Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature 29963523 2018 11 14 2287-979X 53 2 2018 Jun Blood research Blood Res Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. 160-163 10.5045/br.2018.53.2.160 Rastogi Pulkit P Department of Hematology, Postgraduate Institute of Medical Education & Research, Chandigarh, India. Jeyaraman Preethi P Department of Internal (...) Cancer Inst. 2007 Feb 7;99(3):215-22 17284716 Leuk Lymphoma. 2001 Sep-Oct;42(5):1043-8 11697621 Blood. 2011 Feb 10;117(6):1781-91 21148333 Curr Treat Options Oncol. 2014 Jun;15(2):187-209 24652320 Haematologica. 1985 Mar-Apr;70(2):185 3924786 Cancer. 1987 Oct 1;60(7):1537-44 2441843 Blood. 1988 Aug;72(2):655-60 2840988 Leukemia. 2002 Aug;16(8):1454-9 12145685 Cytometry B Clin Cytom. 2011 May;80(3):195-200 21520406

2018 Blood research

7. Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte‐binding anti‐CD antibody microarray Full Text available with Trip Pro

Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte‐binding anti‐CD antibody microarray The morphologic diagnosis of hairy cell leukemia coexisting with another lymphoproliferative disorder is hindered by the small size of hairy cell population. It can be simplified by presorting peripheral blood mononuclear cell using an anti-CD antibody microarray on transparent support (including anti-CD11c, CD25, CD103, and CD123) before

2018 Clinical Case Reports

8. Hairy cell leukemia 2020: Update on diagnosis, risk-stratification, and treatment. Full Text available with Trip Pro

Hairy cell leukemia 2020: Update on diagnosis, risk-stratification, and treatment. Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogeneous group of mature lymphoid B-cell disorders, characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment.Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL (...) immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation.Progression of patients with HCL is based on a large splenomegaly, leukocytosis, a high number of hairy cells in the peripheral blood and the immunoglobulin heavy chain variable region gene mutational status. VH4-34 positive HCL cases are associated with poor prognosis TREATMENT

2019 American journal of hematology

9. Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Full Text available with Trip Pro

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia. Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks (...) of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Conversely, 15 CLL cancer pairs were reciprocally increased. The increased risks were reciprocal for ALL and four cancers. RR for ALL was 15·35 after myeloid neoplasia. HCL showed reciprocally increased RRs with non-Hodgkin lymphoma and melanoma. The concordance between RRs

2019 British journal of haematology

10. Hairy cell leukemia presenting with Ecthyma Gangrenosum- a case report. Full Text available with Trip Pro

Hairy cell leukemia presenting with Ecthyma Gangrenosum- a case report. Ecthyma gangrenosum is a cutaneous infectious usually associated with P. aeruginosa. It usually develops In patients with an underlying immunodeficiency.A 50-year old mentally disabled white male with a history of epilepsy presented with fever and a painless red macule on his right arm which rapidly progressed to a painful ulcer. Blood and lesion cultures revealed P.aeruginosa, confirming our clinical diagnosis of ecthyma (...) gangrenosum. Subsequently an underlying immune deficit was found, namely patient was diagnosed with hairy-cell leukemia. Despite adequate antibiotics no infection control could be achieved. After treating the underlying immune deficit as well, the infection and hairy-cell leukemia resolved completely.Ecthyma gangrenosum is an important cutaneous infection to recognize, because it is it is typically associated with P.aeruginosa bacteremia. Recognizing this skin leasion should prompt empiric antimicrobial

2019 BMC Infectious Diseases

11. Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report Full Text available with Trip Pro

Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report The BRAF-V600E mutation has been established as a signature alteration occurring almost universally in hairy cell leukemia. Moreover, it can be detected in a small percentage of patients with non-small cell lung cancer. We report the case of a patient with a metastatic BRAF-V600E-mutated lung adenocarcinoma suffering from concomitant hairy cell leukemia

2018 Case reports in oncology

12. Image gallery: Hairy-cell leukaemia presenting with Sweet syndrome. Full Text available with Trip Pro

Image gallery: Hairy-cell leukaemia presenting with Sweet syndrome. 30194758 2019 01 03 1365-2133 180 1 2019 Jan The British journal of dermatology Br. J. Dermatol. Image Gallery: Hairy-cell leukaemia presenting with Sweet syndrome. e3 10.1111/bjd.17157 Shah P R PR http://orcid.org/0000-0001-9142-1545 Department of Dermatology, University of Rochester Medical Center, Rochester, NY, U.S.A. Scott G G Department of Dermatology, University of Rochester Medical Center, Rochester, NY, U.S.A. Beck L

2018 British Journal of Dermatology

13. An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (MOXE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03501615 Expanded Access Status : No longer available First Posted : April 18, 2018 Last Update Posted : February 21

2018 Clinical Trials

14. Skeletal involvement of hairy cell leukemia Full Text available with Trip Pro

Skeletal involvement of hairy cell leukemia Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder. Skeletal involvement is an unusual manifestation of HCL, complicating the course of the disease in approximately 3% of patients. We describe a case of skull involvement by HCL, a localization rarely reported in the literature.

2018 Clinical Case Reports

15. Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report Full Text available with Trip Pro

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report Polycythemia vera is a myeloproliferative disease that sometimes evolves to myelofibrosis, causing splenomegaly and neutropenia. In this case report, we describe a patient with polycythemia vera and unexplained neutropenia who later turned out to also have hairy cell leukemia.A middle-aged Caucasian man with polycythemia vera presented to our hospital with chronic mouth ulcers (...) . Later he developed leukopenia and pancytopenia. Bone marrow biopsies showed fibrosis. Further morphological analyses of bone marrow and blood smears revealed probable transformation into acute myeloid leukemia. However, there were also cells indicating hairy cell leukemia. Morphological and immunohistochemical analyses later confirmed the presence of hairy cell leukemia in biopsies that had been present for 3 years. Treatment with cladribine temporarily reversed the patient's neutropenia.Hairy cell

2018 Journal of medical case reports

16. Recent advances in understanding and managing hairy cell leukemia Full Text available with Trip Pro

Recent advances in understanding and managing hairy cell leukemia Hairy cell leukemia is a rare B-cell malignancy that is characterized by an indolent course. It was initially described as a distinct entity in 1958. Before the establishment of modern treatment, median survival was only 4 years. Since then, major advances in the treatment and understanding of the biology and genomic landscape of hairy cell leukemia have been made. This review summarizes the present understanding of hairy cell (...) leukemia with particular focus on the development of novel and targeted approaches to treatment.

2018 F1000Research

18. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Full Text available with Trip Pro

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days

2018 Leukemia

19. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up. Full Text available with Trip Pro

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up. Anti-CD22 moxetumomab pasudotox achieved 46% complete remissions (CRs) in previously reported phase 1 testing in relapsed/refractory hairy cell leukemia (HCL; n = 28). The importance of minimal residual disease (MRD) after CR in HCL is unknown. A 21-patient extension cohort received 50 µg/kg every other day for 3 doses in 4-week cycles. These patients plus 12 previously reported

2018 Blood

20. Listeria monocytogenes Infection in Hairy Cell Leukemia: A Case Report and Literature Review Full Text available with Trip Pro

Listeria monocytogenes Infection in Hairy Cell Leukemia: A Case Report and Literature Review Listeria monocytogenes infections have been described in patients with diverse types of malignancy, especially leukemia. We report the case of a 65-year-old man with previously untreated hairy cell leukemia characterized by CD5 positivity and trisomy 12 (3% of blood lymphocytes) who developed bacteremia due to L. monocytogenes serotype 1/2b. We summarize clinical features and treatment of this patient (...) and five previously reported patients with hairy cell leukemia who also had L. monocytogenes infections. All six patients were men. Their mean age at infection diagnosis was 70 y. Three men had undergone splenectomy 4-11 y before they developed L. monocytogenes infection. The central nervous system was the primary site of infection in four men. Bacteremia alone occurred in two other men. At diagnosis of infection, one man was receiving antileukemia chemotherapy and another man was receiving treatment

2018 Case reports in hematology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>